Background The development of a safe and effective vaccine against the human
immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. Methods In a …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX …

Summary Background The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of
a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did …

Background The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV
(vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in …

To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in
both high-risk and low-risk persons and to evaluate variations in dosing schedule, we …

More than 2 million AIDS-related deaths occurred globally in 2008, and more than 33 million
people are living with HIV/AIDS. Despite promising advances in prevention, an estimated …

Background Modest efficacy was reported for the HIV vaccine tested in the RV144 trial,
which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120) …

In order to boost immune responses in persons in whom highly active antiretroviral therapy
(HAART) was initiated within 120 days of the onset of symptoms of newly acquired human …

Objective: Evaluate immunogenicity and clinical efficacy of two immunization strategies with
the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients …

Abstract ALVAC-HIV (vCP1521) and AIDSVAX B/E were evaluated in a phase 1/2 trial of
human immunodeficiency virus (HIV)-negative Thai adults. Of 133 volunteers enrolled, 122 …